Clinical Trials in South Korea / NCT07263191
Recruiting
Observational
A Study of Olanzapine in Participants With Bipolar Disorder.
NCT07263191 · tracked via the Priya Life Science South Korea tracker
Condition(s) studied
Bipolar Disorder
Investigational drug(s) / intervention(s)
Olanzapine: As this is a non-interventional study designed to collect data as part of routine clinical practice, the selection and dosage of medication, treatment period, and whether or not to change it are all based on the clinician's judgment.
Study summary
This study aimed to identify treatment patterns in patients with bipolar disorder receiving olanzapine according to demographic and clinical characteristics and to evaluate the effectiveness of education on weight gain, a side effect of olanzapine, in preventing weight gain.
Eligibility
Inclusion Criteria:
* Patients who have signed the informed consent after receiving information about the purpose and method of this study.
* Patients diagnosed with bipolar disorder and scheduled to receive olanzapine.
* Patients who understand the contents of the survey and can answer the questions directly.
Exclusion Criteria:
* Female patients who are pregnant, have childbearing potential, or are breastfeeding.
* Has received an investigational product within 12 weeks from the study enrollment or has plans to participate in another clinical trial during the participation of this study.
* Other subjects who are considered inappropriate to participate in this study by the judgment of the investigator.
Primary outcome measure(s)
- Treatment pattern — Baseline, 8weeks, 12weeks
Frequency and percentage of the therapeutic class of bipolar disorder agents administered within 8 weeks prior to baseline will be presented based on the patients' demographic factors and clinical characteristics. Furthermore, frequency and percentage of the therapeutic class patterns of bipolar disorder agents administered after baseline will be presented
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| CHA Bundang Medical Center | Seongnam | South Korea | Recruiting |
More Boryung Pharmaceutical Co., Ltd trials in South Korea
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07263191 on ClinicalTrials.gov ↗ ← All trials in South Korea